A citation-based method for searching scientific literature

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai, Noriaki Sakuragi, Hidemichi Watari, Nobutaka Takahashi, Hidenori Kato, Kosei Hasegawa, Kan Yonemori, Mika Mizuno, Kazuhiro Takehara, Hitoshi Niikura, Takashi Sawasaki, Sari Nakao, Toshiaki Saito, Takayuki Enomoto, Satoru Nagase, Nao Suzuki, Takashi Matsumoto, Eiji Kondo, Kenzo Sonoda, Satomi Aihara, Yoichi Aoki, Aikou Okamoto, Hirokuni Takano, Hiroshi Kobayashi, Hisamori Kato, Yoshito Terai, Akira Takazawa, Yusuke Takahashi, Yoshinobu Namba, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama, Ikuo Konishi. J Clin Oncol 2021
Times Cited: 13







List of co-cited articles
89 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
662
61

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
226
53

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen N Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Mäenpää,[...]. J Clin Oncol 2021
41
46

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, Amit M Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard, Gary E Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee,[...]. Lancet Oncol 2021
30
46

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
182
38

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
105
38

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
978
38

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng. Cancer Res 2019
197
30

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
30

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Erika J Lampert, Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R Nair, Yingmiao Liu, Elizabeth M Swisher, James W Hodge, Andrew B Nixon, Erin Nichols,[...]. Clin Cancer Res 2020
51
30

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
167
30

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
30

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Dmitriy Zamarin, Robert A Burger, Michael W Sill, Daniel J Powell, Heather A Lankes, Michael D Feldman, Oliver Zivanovic, Camille Gunderson, Emily Ko, Cara Mathews,[...]. J Clin Oncol 2020
87
30

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Emese Zsiros, Sarah Lynam, Kristopher M Attwood, Chong Wang, Shanmuga Chilakapati, Eduardo Cortes Gomez, Song Liu, Stacey Akers, Shashikant Lele, Peter J Frederick,[...]. JAMA Oncol 2021
22
30

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
30

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
830
30

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee,[...]. Clin Cancer Res 2017
430
30

Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
Panagiotis A Konstantinopoulos, Stephen A Cannistra. J Clin Oncol 2021
5
60

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, Scott Rodig, Lauren L Ritterhouse, Joyce F Liu, Judy E Garber, Dipanjan Chowdhury, Catherine J Wu, Alan D D'Andrea,[...]. Oncotarget 2016
356
23

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter Mottram, Melina Evdemon-Hogan, Jose R Conejo-Garcia, Lin Zhang, Matthew Burow,[...]. Nat Med 2004
23

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Joyce F Liu, Christina Herold, Kathryn P Gray, Richard T Penson, Neil Horowitz, Panagiotis A Konstantinopoulos, Cesar M Castro, Sarah J Hill, Jennifer Curtis, Weixiu Luo,[...]. JAMA Oncol 2019
72
23

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
23

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
833
23

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee. N Engl J Med 2017
23

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J Birrer, Rene dePont Christensen, Gitte-Bettina Nyvang, Susanne Malander, Maarit Anttila, Theresa L Werner, Bente Lund, Gabriel Lindahl,[...]. Lancet Oncol 2019
97
23

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Joyce F Liu, William T Barry, Michael Birrer, Jung-Min Lee, Ronald J Buckanovich, Gini F Fleming, Bj Rimel, Mary K Buss, Sreenivasa Nattam, Jean Hurteau,[...]. Lancet Oncol 2014
383
23

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
461
23

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
544
23

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
23

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Joyce F Liu, Michael Gordon, Jennifer Veneris, Fadi Braiteh, Ani Balmanoukian, Joseph Paul Eder, Ana Oaknin, Erika Hamilton, Yulei Wang, Indrani Sarkar,[...]. Gynecol Oncol 2019
49
23

Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse.
Silke Reinartz, Tim Schumann, Florian Finkernagel, Annika Wortmann, Julia M Jansen, Wolfgang Meissner, Michael Krause, Anne-Marie Schwörer, Uwe Wagner, Sabine Müller-Brüsselbach,[...]. Int J Cancer 2014
162
15

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
J P Neijt, S A Engelholm, M K Tuxen, P G Sorensen, M Hansen, C Sessa, C A de Swart, F R Hirsch, B Lund, H C van Houwelingen. J Clin Oncol 2000
339
15

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar, Dan G Duda, Rakesh K Jain. Nat Rev Clin Oncol 2018
588
15

Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
Christopher B Morse, Mirna N Toukatly, Mark R Kilgore, Kathy J Agnew, Sarah S Bernards, Barbara M Norquist, Kathryn P Pennington, Rochelle L Garcia, John B Liao, Elizabeth M Swisher. Gynecol Oncol 2019
16
15

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Robert F Ozols, Brian N Bundy, Benjamin E Greer, Jeffrey M Fowler, Daniel Clarke-Pearson, Robert A Burger, Robert S Mannel, Koen DeGeest, Ellen M Hartenbach, Rebecca Baergen. J Clin Oncol 2003
15

Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Katsutoshi Oda, Junzo Hamanishi, Koji Matsuo, Kosei Hasegawa. Gynecol Oncol 2018
58
15

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Brooke E Howitt, Kyle C Strickland, Lynette M Sholl, Scott Rodig, Lauren L Ritterhouse, Dipanjan Chowdhury, Alan D D'Andrea, Ursula A Matulonis, Panagiotis A Konstantinopoulos. Oncoimmunology 2017
64
15

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
M J Piccart, K Bertelsen, K James, J Cassidy, C Mangioni, E Simonsen, G Stuart, S Kaye, I Vergote, R Blom,[...]. J Natl Cancer Inst 2000
748
15

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Jianfeng Shen, Zhenlin Ju, Wei Zhao, Lulu Wang, Yang Peng, Zhongqi Ge, Zachary D Nagel, Jun Zou, Chen Wang, Prabodh Kapoor,[...]. Nat Med 2018
208
15

Tumor microenvironment: the role of the tumor stroma in cancer.
Hanchen Li, Xueli Fan, Jeanmarie Houghton. J Cell Biochem 2007
401
15

Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Xia Yuan, Jing Zhang, Dan Li, Ye Mao, Fei Mo, Wei Du, Xuelei Ma. Gynecol Oncol 2017
107
15

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Chia-Wei Li, Seung-Oe Lim, Weiya Xia, Heng-Huan Lee, Li-Chuan Chan, Chu-Wei Kuo, Kay-Hooi Khoo, Shih-Shin Chang, Jong-Ho Cha, Taewan Kim,[...]. Nat Commun 2016
409
15

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Liang Cao, Maria I Harrell, Elizabeth M Swisher, Nicole Houston,[...]. J Clin Oncol 2017
147
15

Alternative activation of macrophages.
Siamon Gordon. Nat Rev Immunol 2003
15

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W P McGuire, W J Hoskins, M F Brady, P R Kucera, E E Partridge, K Y Look, D L Clarke-Pearson, M Davidson. N Engl J Med 1996
15

A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.
Meiying Zhang, Yifeng He, Xiangjun Sun, Qing Li, Wenjing Wang, Aimin Zhao, Wen Di. J Ovarian Res 2014
272
15

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Praveen Vikas, Nicholas Borcherding, Adithya Chennamadhavuni, Rohan Garje. Front Oncol 2020
54
15


IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R Kaufman, Andrew Albright, Jonathan D Cheng, S Peter Kang, Veena Shankaran,[...]. J Clin Invest 2017
15

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, Jiyoung Ahn, Brian Bundy, Hiroyoshi Nishikawa, Feng Qian, Achim A Jungbluth, Denise Frosina, Sacha Gnjatic, Christine Ambrosone,[...]. Proc Natl Acad Sci U S A 2005
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.